Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms-Reference-Cited by-同舟云学术

Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms

Published:2020-11-20 Issue:6519 Volume:370 Page:950-957
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Tortorici M. Alejandra¹²^ORCID,Beltramello Martina³^ORCID,Lempp Florian A.⁴,Pinto Dora³,Dang Ha V.¹^ORCID,Rosen Laura E.⁴^ORCID,McCallum Matthew¹^ORCID,Bowen John¹^ORCID,Minola Andrea³,Jaconi Stefano³,Zatta Fabrizia³,De Marco Anna³^ORCID,Guarino Barbara³^ORCID,Bianchi Siro³^ORCID,Lauron Elvin J.⁴,Tucker Heather⁴^ORCID,Zhou Jiayi⁴^ORCID,Peter Alessia³^ORCID,Havenar-Daughton Colin⁴^ORCID,Wojcechowskyj Jason A.⁴^ORCID,Case James Brett⁵^ORCID,Chen Rita E.⁵,Kaiser Hannah⁴^ORCID,Montiel-Ruiz Martin⁴^ORCID,Meury Marcel⁴^ORCID,Czudnochowski Nadine⁴^ORCID,Spreafico Roberto⁴^ORCID,Dillen Josh⁴^ORCID,Ng Cindy⁴^ORCID,Sprugasci Nicole³^ORCID,Culap Katja³^ORCID,Benigni Fabio³^ORCID,Abdelnabi Rana⁶^ORCID,Foo Shi-Yan Caroline⁶^ORCID,Schmid Michael A.³^ORCID,Cameroni Elisabetta³^ORCID,Riva Agostino⁷^ORCID,Gabrieli Arianna⁷^ORCID,Galli Massimo⁷^ORCID,Pizzuto Matteo S.³^ORCID,Neyts Johan⁶^ORCID,Diamond Michael S.⁵^ORCID,Virgin Herbert W.⁴⁸⁹^ORCID,Snell Gyorgy⁴,Corti Davide³,Fink Katja³^ORCID,Veesler David¹^ORCID

Affiliation:

1. Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.

2. Institut Pasteur and CNRS UMR 3569, Unité de Virologie Structurale, Paris, France.

3. Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.

4. Vir Biotechnology, San Francisco, CA 94158, USA.

5. Departments of Medicine, Molecular Microbiology, Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.

6. Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Belgium.

7. III Division of Infectious Diseases, Luigi Sacco University Hospital, University of Milan, Italy.

8. Washington University School of Medicine, St. Louis, MO, USA.

9. UTSouthwestern Medical Center, Dallas, TX, USA.

Abstract

A strong cocktail against SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is initiated by the trimeric spike protein that decorates the virus and binds the ACE2 receptor. Antibodies against the spike that neutralize viral infection have potential as therapeutics. Tortorici et al. describe two very potent antibodies, S2E12 and S2M11. Electron microscopy structures characterized the binding and showed that S2E12 traps the spike in a conformation that cannot bind ACE2. Both antibodies protected hamsters against SARS-CoV-2 challenge and may be useful in antibody cocktails to combat the virus and prevent the development of resistance. Science , this issue p. 950

Funder

National Institute of General Medical Sciences

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference83 articles.

1. A pneumonia outbreak associated with a new coronavirus of probable bat origin

2. A Novel Coronavirus from Patients with Pneumonia in China, 2019

3. A Novel Bat Coronavirus Closely Related to SARS-CoV-2 Contains Natural Insertions at the S1/S2 Cleavage Site of the Spike Protein

4. Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory Syndrome

5. A Novel Coronavirus Associated with Severe Acute Respiratory Syndrome

Cited by 512 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A quadri-fluorescence SARS-CoV-2 pseudovirus system for efficient antigenic characterization of multiple circulating variants;Cell Reports Methods;2024-09

2. Structure and inhibition of SARS-CoV-2 spike refolding in membranes;Science;2024-08-16

3. Immune and inflammation features of severe and critical Omicron infected patients during Omicron wave in China;BMC Infectious Diseases;2024-08-09

4. Human coronavirus HKU1 recognition of the TMPRSS2 host receptor;Cell;2024-08

5. Mapping immunodominant sites on the MERS-CoV spike glycoprotein targeted by infection-elicited antibodies in humans;Cell Reports;2024-08